This trial is comparing the effect of immunotherapy with atezolizumab in combination with standard chemotherapy versus standard therapy alone for the treatment of poorly differentiated extrapulmonary small cell neuroendocrine cancer.
1 Primary · 4 Secondary · Reporting Duration: Up to 5 years from study enrollment
Active Control
Experimental Treatment
189 Total Participants · 4 Treatment Groups
Primary Treatment: Cisplatin · No Placebo Group · Phase 2 & 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: